Table 1.
Baseline demographic, clinical, and tumor characteristics before adjustment.
| Characteristic | Overall population | NOVA study-like subpopulation | ||
|---|---|---|---|---|
| 2LM niraparib monotherapy (N = 199) | AS (N = 707) | 2LM niraparib monotherapy (N = 123) | AS (N = 143) | |
| Age at index, median (IQR), years | 68 (61–75) | 69 (60–76) | 68.0 (61.0–74.0) | 69.0 (60.0–78.0) |
| Age group at index, n (%) | ||||
| 18–74 years | 146 (73.4) | 498 (70.4) | 94 (76.4) | 94 (65.7) |
| ⩾75 years | 53 (26.6) | 209 (29.6) | 29 (23.6) | 49 (34.3) |
| Race, n (%) | ||||
| White | 132 (66.3) | 508 (71.9) | 87 (70.7) | 112 (78.3) |
| Other a | 61 (30.7) | 157 (22.2) | 32 (26.0) | 24 (16.8) |
| Unknown | 6 (3.0) | 42 (5.9) | 4 (3.3) | 7 (4.9) |
| Practice type, n (%) | ||||
| Academic b | 18 (9.0) | 118 (16.7) | 14 (11.4) | 8 (5.6) |
| Community | 168 (84.4) | 574 (81.2) | 99 (80.5) | 129 (90.2) |
| Both | 13 (6.5) | 15 (2.1) | 10 (8.1) | 6 (4.2) |
| Region, n (%) c | ||||
| Midwest | 20 (10.1) | 76 (10.7) | 14 (11.4) | 22 (15.4) |
| Northeast | 17 (8.5) | 73 (10.3) | 8 (6.5) | 19 (13.3) |
| South | 107 (53.8) | 308 (43.6) | 64 (52.0) | 64 (44.8) |
| West | 22 (11.1) | 94 (13.3) | 12 (9.8) | 18 (12.6) |
| Other/unknown | 33 (16.6) | 156 (22.1) | 25 (20.3) | 20 (14.0) |
| Weight, n (%) d | ||||
| <77 kg | 120 (60.3) | 464 (65.6) | 68 (55.3) | 95 (66.4) |
| ⩾77 kg | 79 (39.7) | 243 (34.4) | 55 (44.7) | 48 (33.6) |
| Unknown | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| ECOG performance status, n (%) | ||||
| 0–1 | 167 (83.9) | 505 (71.4) | 123 (100.0) | 143 (100.0) |
| 2–4 | 18 (9.0) | 93 (13.2) | 0 (0.0) | 0 (0.0) |
| Unknown | 14 (7.0) | 109 (15.4) | 0 (0.0) | 0 (0.0) |
| Disease stage at diagnosis, n (%) | ||||
| I–II | 21 (10.6) | 77 (10.9) | 14 (11.4) | 21 (14.7) |
| III | 103 (51.8) | 353 (49.9) | 66 (53.7) | 87 (60.8) |
| IV | 56 (28.1) | 203 (28.7) | 36 (29.3) | 28 (19.6) |
| Unknown or missing | 19 (9.5) | 74 (10.5) | 7 (5.7) | 7 (4.9) |
| Epithelial histology, n (%) e | ||||
| Serous | 156 (78.4) | 545 (77.1) | 98 (79.7) | 116 (81.1) |
| Other | 20 (10.1) | 68 (9.6) | 14 (11.4) | 14 (9.8) |
| Epithelial NOS/unknown | 23 (11.6) | 94 (13.3) | 11 (8.9) | 13 (9.1) |
| HRD status, n (%) f | ||||
| HRD status known | 17 (8.5) | 94 (13.3) | 9 (7.3) | 20 (14.0) |
| Unknown | 182 (91.5) | 613 (86.7) | 114 (92.7) | 123 (86.0) |
| Treatment lines after index, n (%) | ||||
| 0 | 69 (34.7) | 185 (26.2) | 47 (38.2) | 43 (30.1) |
| 1 | 64 (32.2) | 221 (31.3) | 37 (30.1) | 37 (25.9) |
| 2 | 25 (12.6) | 137 (19.4) | 14 (11.4) | 33 (23.1) |
| 3+ | 41 (20.6) | 164 (23.2) | 25 (20.3) | 30 (21.0) |
| Used bevacizumab before 2L maintenance therapy, n (%) g | 73 (36.7) | 310 (43.8) | 41 (33.3) | 60 (42.0) |
| Platinum-based therapy during 2L treatment, n (%) | 195 (98.0) | 277 (39.2) | 123 (100.0) | 143 (100.0) |
| Duration between end of 1L and start of 2L, median (IQR), months | 13.6 (7.6–20.9) | 6.2 (2.1–12.5) | 16.1 (10.8–26.6) | 14.2 (10.8–28.7) |
| Duration of follow-up, median (IQR), months | 15.6 (9.1–27.1) | 9.3 (3.2–21.0) | 16.8 (10.4–28.7) | 10.2 (4.1–23.7) |
Other may include race categories provided in the database of “Black or African American,” “Asian,” “Hispanic or Latino,” and “Other Race.”
Academic may include both university and non-university academic settings.
Patients from academic practices had unknown geographic regions. Patients in Puerto Rico were grouped into other/unknown because of low numbers.
Defined as the most recent body weight recorded from initial diagnosis to index date.
Patients with unknown histology were excluded in the NOVA study-like subpopulation.
HRD status was defined as patients who ever had a positive or negative result were grouped as status known, remaining patients who only had an unknown result or were never tested were grouped as unknown. Positive/negative categories with less than five patients were combined to protect patient confidentiality.
Defined as the use of bevacizumab as part of a line of therapy prior to index, including 1L, 1L maintenance, and/or 2L.
1L, first line; 2L, second line; 2LM, second-line maintenance; AS, active surveillance; ECOG, Eastern Cooperative Oncology Group; HRD, homologous recombination deficiency; IQR, interquartile range; NOS, not otherwise specified.